Syntimmune’s lead candidate, SYNT001, is a monoclonal antibody that blocks the FcRn–IgG interaction and is being developed to treat a broad range of IgG-mediated autoimmune diseases. The company is conducting two ongoing Phase 1b/2a trials of SYNT001 in pemphigus and warm autoimmune hemolytic anemia, and U.S. Phase 1a data showed safe and rapid onset of clinically meaningful FcRn–IgG blockade. Syntimmune is also developing SYNT002, which targets the FcRn–albumin interaction and promotes clearance of albumin-bound endo- and exotoxins. The Series B proceeds will fund continued clinical development of SYNT001, manufacturing scale-up in preparation for anticipated registration studies, further preclinical development of SYNT002, and additional research activities. Since its founding, the company has received a total of $78 million in capital commitments from life sciences investors led by Apple Tree Partners. The company was founded in 2013 by Richard Blumberg, M.D., and Laurence Blumberg, M.D. Syntimmune is a clinical-stage biotech advancing therapies for IgG-mediated autoimmune diseases based on neonatal Fc receptor (FcRn) biology. Its lead candidate, SYNT001, is a biologic that specifically blocks FcRn–IgG interactions and is advancing into multiple Phase 1b/2a trials. The company is also developing two earlier-stage therapeutic programs targeting other unique aspects of FcRn biology. Syntimmune intends to use the proceeds from its latest funding to advance its Phase 1b/2a studies. As of the article, the company had raised $28M in total capital to date. The company was founded in 2013 and is based in Newton, MA and New York, NY. Leadership includes founder Dr. Laurence Blumberg (COO) and new President and CEO David de Graaf, Ph.D. Syntimmune is a development-stage company advancing novel therapies that target the neonatal Fc receptor (FcRn) to treat IgG-mediated autoimmune diseases. Its lead candidate, SYNT001, is a biologic that blocks the FcRn–IgG interaction and has completed preclinical proof of concept and safety testing. The company intends to submit an IND for SYNT001 to the FDA in mid-2016 and plans a Phase 1a trial in healthy volunteers later in the year. Syntimmune also has two additional earlier-stage therapeutic programs targeting other aspects of FcRn biology. Since its founding in 2013, Syntimmune has received $28 million in funding commitments from life sciences investors, including Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund. Funds from the recently triggered financing tranche will be used to complete the anticipated Phase 1a study.

Total raised

$68M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2017